Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study
Xiang-Chong Luo, Peng Tang, Pei-Xiong Zhong · 2024
Read Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study by Xiang-Chong Luo, Peng Tang, Pei-Xiong Zhong (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11625108.txt.
Description
Xiang-Chong Luo, Peng Tang, and Pei-Xiong Zhong review one hundred fifty lung cancer patients to see what a vessel-blocking drug adds to chemoradiation, in a 2024 study. The drug, bevacizumab, starves tumors by cutting their blood supply signal. Serum levels of two growth signals and one regulatory RNA were compared before and after treatment, and patients were split by how well they responded.
After treatment, both growth signals fell and the RNA rose, more so in the drug group than in controls, matching a higher response rate. Statistical modeling named three independent drivers of success: how long the disease had run, tumor diameter, and the treatment regimen itself. The authors conclude the combination works better and safely, and they advise weighing those three factors when planning therapy. The study is retrospective, from one hospital's records.
Catalog record
| CREATOR | Xiang-Chong Luo, Peng Tang, Pei-Xiong Zhong |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |